ClinicalTrials.gg
WithdrawnNCT04483687SEALION1-IRUpdated Jan 11, 2021

Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Have an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drug Therapy

A Phase 3 interventional study of Filgotinib and Placebo to Match Filgotinib in Ankylosing Spondylitis, sponsored by Gilead Sciences. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-11.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Why this study was withdrawn
Development program terminated

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The primary objective of this study is to evaluate the effect of filgotinib versus placebo on signs and symptoms of active ankylosing spondylitis (AS), evaluated by Assessment of SpondyloArthritis international Society 40% improvement (ASAS40) response at Week 16 in participants with active AS who have an inadequate response to biologic disease-modifying antirheumatic drug therapy.

Read the detailed description

The study consists of 2 parts: Main Study (screening through Week 16) and Long-Term Extension (LTE) (up to 1.5 years after Week 16). Participants who permanently discontinue treatment in the Main Study will not be eligible for the Long-Term extension.

02

Conditions studied

  • Ankylosing Spondylitis
03

In context

Spondylitis, Ankylosing

533 studies on the registry are indexed under Spondylitis, Ankylosing; 99 are open to participants now.

Browse Spondylitis, Ankylosing studies →

Lead sponsor

Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.

Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Ambulatory male or female individuals who are ≥ 18 years of age (≥ 20 years of age in Japan) on the day of signing
  • Have had inadequate response or intolerance to at least 1 and not more than 3 biologic disease-modifying antirheumatic drugs (bioDMARDs) administered for the treatment of ankylosing spondylitis (AS) or inflammatory arthritis
  • Have an established diagnosis of radiographic axial spondyloarthritis (SpA)/ AS by a rheumatologist (or other specialist with expertise in diagnosing AS)
  • Meet Assessment of SpondyloArthritis international Society (ASAS) classification criteria for axial SpA with radiographic sacroiliitis on imaging at screening as follows:

    • History of back pain ≥ 3 months and age at onset of back pain \< 45 years, AND
    • Radiographic sacroiliitis Grade ≥ 2 bilaterally or Grade 3-4 unilaterally, AND
    • ≥ 1 SpA feature (refer to protocol; inflammatory back pain, arthritis, heel enthesitis, uveitis anterior, dactylitis, psoriasis, inflammatory bowel disease (IBD), good response to nonsteroidal anti-inflammatory drugs (NSAIDs), family history of SpA, historically positive human leukocyte antigen B27 (HLA-B27), elevated C-reactive protein (CRP))
  • Have active AS at screening and Day 1 as defined by:

    • Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ≥ 4, AND
    • Spinal pain ≥ 4 (based on BASDAI question 2)
  • Have a history of inadequate response or intolerance to NSAIDs for the treatment of AS
  • If using allowed conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), NSAID, or therapy, must have been on stable doses (as outlined in protocol) prior to Day 1

Key Exclusion Criteria:

  • Prior exposure to a Janus kinase (JAK) inhibitor > 2 doses
  • Total ankylosis of the spine
  • Any active/recent infection, as specified in the protocol
  • Diagnosis of fibromyalgia
  • Any musculoskeletal disorder other than AS that would interfere with assessment of study parameters, as per judgement of investigator

    • Note: Prior history of reactive or other types of inflammatory arthritis is permitted if there is documentation of change in diagnosis to AS or additional diagnosis of AS
  • Any history of an inflammatory arthritis with onset age before 16 years old

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Filgotinib 200 mg (Main Study - Blinded)

    Participants will receive filgotinib 200 mg + placebo to match (PTM) filgotinib 100 mg for up to 16 weeks.

    Drug: Filgotinib · Drug: Placebo to Match Filgotinib

  • Experimental
    Filgotinib 100 mg (Main Study - Blinded)

    Participants will receive filgotinib 100 mg + PTM filgotinib 200 mg for up to 16 weeks.

    Drug: Filgotinib · Drug: Placebo to Match Filgotinib

  • Placebo comparator
    Placebo (Main Study - Blinded)

    Participants will receive PTM filgotinib 200 mg + PTM filgotinib 100 mg for up to 16 weeks.

    Drug: Placebo to Match Filgotinib

  • Experimental
    Filgotinib 200 mg (LTE)

    Before study-wide unblinding, participants will receive filgotinib 200 mg + PTM filgotinib 100 mg. After study-wide unblinding, participants will receive filgotinib 200 mg.

    Drug: Filgotinib · Drug: Placebo to Match Filgotinib

  • Experimental
    Filgotinib 100 mg (LTE)

    Before study-wide unblinding, participants will receive filgotinib 100 mg + PTM filgotinib 200 mg. After study-wide unblinding, participants will receive filgotinib 100 mg.

    Drug: Filgotinib · Drug: Placebo to Match Filgotinib

Interventions

  • Tablets administered orally once daily

    Also known as: GS-6034, GLPG0634

  • DrugPlacebo to Match Filgotinib

    Tablets administered orally once daily

06

What researchers measure

Primary outcomes

  1. Proportion of Participants Who Achieve an Assessment of SpondyloArthritis international Society 40% Improvement (ASAS40) Response at Week 16

    The ASAS40 calculation involves the analysis of 4 domains: participant's global assessment of disease activity, spinal pain (derived from the spinal pain questionnaire), function (derived from Bath Ankylosing Spondylitis Functional Index (BASFI) score), and inflammation (derived from morning stiffness questions from Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)). The ASAS40 is achieved if there is an improvement of ≥ 40% and ≥ 2 units in at least 3 domains on a scale of 10 with no worsening in the remaining domain.

    Time frame: Week 16

Secondary outcomes

  1. Proportion of Participants Who Achieve an ASAS40 Response

    The ASAS40 calculation involves the analysis of 4 domains: participant's global assessment of disease activity, spinal pain (derived from the spinal pain questionnaire), function (derived from BASFI score), and inflammation (derived from morning stiffness questions from BASDAI). The ASAS40 is achieved if there is an improvement of ≥ 40% and ≥ 2 units in at least 3 domains on a scale of 10 with no worsening in the remaining domain.

    Time frame: Up to Week 12

  2. Proportion of Participants Who Achieve an Assessment of SpondyloArthritis international Society 20% Improvement (ASAS20) Response

    The ASAS20 calculation involves the analysis of 4 domains: participant's global assessment of disease activity, spinal pain (derived from the spinal pain questionnaire), function (derived from BASFI score), and inflammation (derived from morning stiffness questions from BASDAI).The ASAS20 is achieved if there is an improvement of ≥ 20% and ≥ 1 units in at least 3 domains on a scale of 10 with no worsening of ≥ 20% and ≥ 1 unit in the remaining domain.

    Time frame: Up to Week 16

  3. Proportion of Participants who achieve Ankylosing Spondylitis Disease Activity Score (ASDAS) Low Disease Activity (LDA) (ie, ASDAS < 2.1) at Week 16

    ASDAS is a composite score of 5 domains: total back pain, peripheral pain and/or swelling, duration of morning stiffness (derived from BASDAI questionnaire), participant's global assessment of disease activity, and serum high-sensitivity C-reactive protein (hsCRP). The ASDAS has a continuous scale from 0 with no defined upper end. A lower score indicate lower disease activity. ASDAS LDA is achieved when ASDAS \< 2.1.

    Time frame: Week 16

  4. Proportion of Participants Who Achieve an ASAS 5/6 Response

    The ASAS 5/6 is achieved when at least 20% improvement in at least 5 out of 6 domains. The 6 domains to use are: participant's global assessment of disease activity, spinal pain (derived from the spinal pain questionnaire), function (derived from BASFI score), inflammation (derived from morning stiffness questions from BASDAI), lateral spinal flexion (Bath Ankylosing Spondylitis Metrology Index (BASMI) question 1), and hsCRP.

    Time frame: Up to Week 16

  5. Change from Baseline in the Individual Components of the ASAS Core Set

    ASAS core set consists of 6 assessment domains: (1) participant's global assessment of disease activity, (2) spinal pain (derived from the spinal pain questionnaire), (3) function (derived from BASFI score), (4) inflammation (derived from morning stiffness questions from BASDAI), (5) hsCRP, (for these 5 domains, a lower score indicate lower disease activity) and (6) lateral spinal flexion (BASMI question 1) (for this 6th domain; a higher score indicate lower disease activity).

    Time frame: Baseline and up to Week 16

  6. Proportion of Participants Who Achieve a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 50% Improvement Response

    BASDAI consists of 6 items asking participants to report their fatigue, spinal pain, peripheral arthritis, enthesitis, intensity, and duration of morning stiffness during the past week on a 0 to 10 numeric rating scale. The total score ranges 0-10; scores of 4 or greater suggest suboptimal control of disease. BASDAI 50% improvement is achieved when a decrease in BASDAI versus baseline by at least 50%.

    Time frame: Up to Week 16

  7. Change From Baseline in ASDAS

    ASDAS is a composite score of 5 domains: total back pain, peripheral pain and/or swelling, duration of morning stiffness (derived from BASDAI questionnaire), participant's global assessment of disease activity, and hsCRP. The ASDAS has a continuous scale from 0 with no defined upper end. A lower score indicates lower disease activity.

    Time frame: Baseline and up to Week 16

  8. Change From Baseline in BASDAI

    BASDAI consists of 6 items asking participants to report their fatigue, spinal pain, peripheral arthritis, enthesitis, intensity, and duration of morning stiffness during the past week on a 0 to 10 numeric rating scale. The total score ranges 0-10; scores of 4 or greater suggest suboptimal control of disease.

    Time frame: Baseline and up to Week 16

  9. Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI)

    The BASFI evaluates physical function in AS. The instrument consists of 10 items, rated on a 0 to 10 numeric rating scale (NRS), where 0 represents "easy" and 10 represents "impossible." Among the 10 items, 8 items evaluate basic activities of daily living (putting on socks, bending, reaching up, 2 items on getting up, standing, climbing steps, and looking over shoulder) and 2 items assess participants' ability to cope with everyday life (physically demanding activities and full day's activities). The total score ranges 0-10, and the higher the score, the higher the functional impairment.

    Time frame: Baseline and up to Week 16

  10. Change From Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI) (Linear Score)

    The BASMI combines 5 measures: lateral spinal flexion, tragus-to-wall distance, lumbar flexion (modified Schober index), maximal intermalleolar distance, and cervical rotation. The BASMI will be scored using a linear function that will quantify the mobility of the axial skeleton and allow for objective assessment of clinically significant changes in spinal movement. The total score ranges 0-10, and the higher the score, the more severe the participant's limitation on movement.

    Time frame: Baseline and up to Week 16

  11. Change From Baseline in Chest Expansion

    Chest expansion will be measured during maximal inspiration and maximal forced expiration at the fourth intercostal space.

    Time frame: Baseline and up to Week 16

  12. Change From Baseline in Occiput-to-wall Distance

    Occiput-to-wall distance is measured twice with the participant's heels and back rested against the wall. The chin should be at usual carrying level and the participant takes maximal effort to touch the head against the wall. The distance between the occiput and the wall is assessed and the better of the 2 assessments is to be reported.

    Time frame: Baseline and up to Week 16

  13. Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES), in Participants With Enthesitis at Baseline

    MASES is based on enthesitis grading of 13 body sites. The MASES is the sum of all site scores and ranges from 0-13. The higher the score, the higher the presence of enthesitis.

    Time frame: Baseline and up to Week 16

  14. Change From Baseline in Ankylosing Spondylitis Quality of Life (ASQoL)

    The ASQoL assesses health-related quality of life in AS participants. The questionnaire consists of 18 yes/no questions. A single point will be assigned for each "yes" response, resulting in a total score between 0 and 18, with lower scores indicating a better quality of life.

    Time frame: Baseline and up to Week 16

  15. Change From Baseline in Assessment of SpondyloArthritis international Society Health Index (ASAS HI)

    The ASAS HI is a 17-item patient-reported outcome measure to assess the impact of interventions for spondyloarthritis (SpA), including axial SpA. Each item consists of a question with a binary response of either "I agree" (scored as 1) or "I do not agree" (scored as 0). The scoring is performed by summing the number of "yes" answers. The total sum of the ASAS HI ranges 0-17, with a lower score indicating a better health status.

    Time frame: Baseline and up to Week 16

  16. Change From Baseline in Physical Component Summary (PCS) Score of the 36-Item Short-Form Survey (SF-36) Version 2

    The SF-36 Version 2 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health perceptions, mental health, social functioning, vitality, and 2 component scores (Mental Component Summary (MCS) score and PCS). MCS consists of social functioning, vitality, mental health, and role-emotional. PCS consists of physical functioning, bodily pain, role-physical, and general health perceptions. Each domain will be scored by summing the individual items and transforming the scores into a 0 to 100 scale with higher scores indicating better health status or functioning.

    Time frame: Baseline and up to Week 16

  17. Change From Baseline in Mental Component Summary (MCS) Score of the SF-36 Version 2

    The SF-36 Version 2 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health perceptions, mental health, social functioning, vitality, and 2 component scores (MCS and PCS). MCS consists of social functioning, vitality, mental health, and role-emotional. PCS consists of physical functioning, bodily pain, role-physical, and general health perceptions. Each domain will be scored by summing the individual items and transforming the scores into a 0 to 100 scale with higher scores indicating better health status or functioning.

    Time frame: Baseline and up to Week 16

  18. Change from Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue Scale (FACIT-Fatigue)

    The FACIT-Fatigue measures an individual's level of fatigue during their usual daily activities during the past week. It consists of 13 questions on a 5-point Likert scale, with 0 indicating "not at all" and 4 indicating "very much". Negatively stated items are reversed and the total score ranges 0-52. Low scores indicate more severe fatigue than high scores.

    Time frame: Baseline and up to Week 16

  19. Change From Baseline in Work Productivity and Activity Impairment for Ankylosing Spondylitis (WPAI-AS)

    The WPAI-AS is a questionnaire developed to measure impairments in work activities in participants with AS. The questionnaire consists of 6 questions (currently employed, work time missed due to AS, work time missed due to other reasons, hours actually worked, degree AS affected productivity while working \[0-10 NRS; with 0 indicating no effect and 10 indicating AS completely prevented the participant from working\], and degree AS affected productivity in regular unpaid activities \[0-10 NRS; with 0 indicating no effect and 10 indicating AS completely prevented the participant's daily activities\]). The recall period for questions 2 through 6 is 7 days. Four main outcomes (expressed in percentages) can be obtained from the WPAI-AS: percentage of work time missed due to AS, percentage of impairment due to AS, percentage of overall work impairment due to AS, and percentage of activity impairment due to AS. Higher numbers indicate greater impairment and less productivity.

    Time frame: Baseline and up to Week 16

  20. Change From Baseline in EuroQol 5 Dimensions 5 Levels (EQ-5D-5L)

    The EQ-5D-5L is a standard measure of health-related quality of life. The tool consists of the EQ-5D-5L descriptive system and the EQ visual analogue scale (VAS). The descriptive part comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Each of these 5 dimensions has 5 levels (no problem, slight problems, moderate problems, severe problems, and extreme problems). Results for each of the 5 dimensions are combined into a 5-digit number to describe the participant's health state. The VAS records the participant's health on a 0-100 mm VAS scale, with 0 indicating "the worst health you can imagine" and 100 indicating "the best health you can imagine." Higher scores of EQ VAS indicate better health.

    Time frame: Baseline and up to Week 16

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2020; primary completion for Jan 2023, 25 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2020
First posted
Jul 23, 2020
StartEst.
Dec 2020
Primary completionEst.
Jan 2023
CompletionEst.
Sep 2024
Last update
Jan 11, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04483687
Lead sponsor
Gilead Sciences
Collaborators
Galapagos NV
Responsible party
Sponsor
First posted
Jul 23, 2020
Start date
Dec 2020 (estimated)
Primary completion
Jan 2023 (estimated)
Completion
Sep 2024 (estimated)
Last update
Jan 11, 2021

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GLPG0634

Start the discussion